RT Journal Article SR Electronic T1 Pharmacologic management of chronic neuropathic pain JF Canadian Family Physician JO Can Fam Physician FD The College of Family Physicians of Canada SP 844 OP 852 VO 63 IS 11 A1 Mu, Alex A1 Weinberg, Erica A1 Moulin, Dwight E. A1 Clarke, Hance YR 2017 UL http://www.cfp.ca/content/63/11/844.abstract AB Objective To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.Quality of evidence A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.Main message Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.Conclusion Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.